MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

Net increase(decrease) in cash and cash...-$80,451K Issuance of common stockin connection with...$109,243K Proceeds from formerparent company with...$100,000K Proceeds from publicofferings$75,200K Proceeds from theissuance of common stock...$2,122K Stock-based compensation$8,319K Accounts payable andother liabilities$5,236K Accretion/amortization of investments,net-$146K Depreciation andamortization$105K Amortization of right-of-useassets - operating$102K Net cash provided by(used in) financing...-$48,508K Net cash used inoperating activities-$31,918K Net cash provided byinvesting activities-$25K Canceled cashflow$286,565K Canceled cashflow$13,908K Net parentinvestment$335,047K Net loss-$33,374K Purchases of property andequipment$25K Payments for offeringcosts$26K Prepaid expenses andother assets$12,359K Operating leaseliabilities-$93K
Cash Flow

First Tracks Biotherapeutics, Inc. (TRAX)

First Tracks Biotherapeutics, Inc. (TRAX)

source: myfinsight.com